Leukemia, Myeloid, Acute: all 3,035 studies
Page 28 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
- Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid LeukemiaCompletedNCT00867672Phase 2
- Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid LeukemiaCompletedNCT00866073Phase 2
- A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00861874Phase 1
- Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskCompletedNCT00860639Phase 3
- Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
- Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1/2
- Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic TrioxideCompletedNCT00850304Phase 2
- Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00844441Not applicable
- Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00840684Phase 1/2
- Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
- Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
- Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00834002Phase 1
- RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSActive, not recruitingNCT00819546Phase 1
- Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
- Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid LeukemiaCompletedNCT00806325
- Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer CellsStatus unknownNCT00799799Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)TerminatedNCT00798213Phase 2
- Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid LeukemiaCompletedNCT00797758Phase 2
- Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationCompletedNCT00795548Phase 2
- Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 YearsCompletedNCT00783653Phase 1/2
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AMLCompletedNCT00780598Phase 2
- Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)TerminatedNCT00779480Phase 1
- HCT Versus CT in Elderly AMLTerminatedNCT00766779Phase 3
- A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML)CompletedNCT00764231Phase 2
- Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid LeukemiaCompletedNCT00762632Phase 1/2
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)CompletedNCT00744081Phase 2
- Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive ChemotherapyCompletedNCT00739388Phase 2
- Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyStatus unknownNCT00728520Phase 2
- Oral Clofarabine for Acute Myeloid LeukemiaCompletedNCT00727766Phase 1
- The Effectiveness of the Neutropenic Diet in Pediatric Oncology PatientsCompletedNCT00726934Not applicable
- Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2Status unknownNCT00718250Phase 1
- Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE StudyStatus unknownNCT00715637Phase 3
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00703300Phase 1
- BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid LeukaemiaCompletedNCT00701766Phase 2
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)CompletedNCT00684918Phase 2
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following TransplantationTerminatedNCT00672152Phase 1
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid LeukemiaTerminatedNCT00660036Phase 1
- Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional CytarabineTerminatedNCT00655395Phase 1/2
- Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
- Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00641030Phase 1
- Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsCompletedNCT00640796Phase 1
- Everolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT00636922Phase 1
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric MalignanciesCompletedNCT00619879
- Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AMLCompletedNCT00606723Phase 3
- A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid LeukemiaWithdrawnNCT00601991Phase 2
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2
- Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years OldCompletedNCT00590837Phase 3
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
- A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid MalignanciesTerminatedNCT00569179Phase 1
- FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AMLStatus unknownNCT00559221Phase 2
- A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic LeukemiaCompletedNCT00559091Phase 2
- A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in ChinaCompletedNCT00559065
- Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old ChildrenCompletedNCT00552825
- Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid LeukemiaStatus unknownNCT00544999Phase 1
- Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT00543972Phase 1
- Natural Killer Cells in Older Patients With Acute Myeloid LeukemiaCompletedNCT00540956Not applicable
- Prospective Database for Acute Myeloblastic LeukemiaStatus unknownNCT00538278Not applicable
- Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)CompletedNCT00530699Phase 1
- Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALLCompletedNCT00529360Phase 1/2
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
- Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)Active, not recruitingNCT00525746
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell VaccinesTerminatedNCT00514189Phase 1
- Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid LeukemiaCompletedNCT00512083Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid LeukemiaStatus unknownNCT00510939Phase 2
- A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00510133Phase 2
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
- Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome PatientsCompletedNCT00504920
- Molecular Epidemiology of Acute Myelogenous LeukemiaStatus unknownNCT00502983
- Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00497991Phase 1
- A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)CompletedNCT00495287Phase 3
- Treosulfan-based Conditioning for Transplantation in AML/MDSCompletedNCT00491634Phase 2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
- SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
- Lomustine and Intermediate Dose Cytarabine in Older Patients With AMLCompletedNCT00480064Phase 3
- NOPHO-AML 2004 Study for Children With Acute Myeloid LeukemiaCompletedNCT00476541Phase 3
- High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AMLCompletedNCT00474006Phase 3
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00470197Phase 1
- Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
- Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00462787Phase 1
- Gemtuzumab Ozogamicin Before Allogeneic Stem Cell TransplantationStatus unknownNCT00460447Phase 1/2
- Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00459524
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00459212Phase 1
- Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1HCompletedNCT00458250Phase 1
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3